Oncolytics Biotech (ONCY) Receivables (2009 - 2026)

Oncolytics Biotech (ONCY) posted quarterly Receivables of $1.1 million for Q4 2025, down 100.0% quarter-over-quarter from $33.1 billion in Q3 2017.

Oncolytics Biotech (ONCY) Receivables (2009 - 2026) Analysis & Trends

Oncolytics Biotech (ONCY) has reported Receivables for 10 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.

In Q4 2025, Receivables changed N/A year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (changed N/A YoY), while the FY2025 annual figure was $1.1 million, changed N/A from the prior year.
Receivables slipped to $1.1 million in Q4 2025 per ONCY's latest filing, from $33.1 billion in the prior quarter.
Across five years, Receivables topped out at $1.1 million in Q4 2025 and bottomed at $1.1 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Oncolytics Biotech	101.16 Mn	101.16 Mn	-	-

Download Data